Newsroom

Press / Medias

LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial...

Sep 14, 2020

more +
News

LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial...

Sep 8, 2020

more +
Publications

Discovering the Therapeutic Potential of Keystone Bacteria in Treating Chronic Diseases

Apr 22, 2020

more +
Press / Medias

French Biotech Licenses Microbiome Therapeutic to Treat Mood Disorders

Apr 17, 2020

more +
News

LNC Therapeutics announces the acquisition of an exclusive worldwide license on the first patent...

Apr 15, 2020

more +
News

LNC Therapeutics Announces Successful GMP Manufacturing of Xla1 for Phase 1 Clinical Trial

Mar 12, 2020

more +

YSOPIA Bioscience © 2021 - all rights reserved terms and conditions